Figure-1 (Figure 1)
Guanfacine Extended-release Tablet, Extended Release
Product Images NDC 60505-3928
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Guanfacine Extended-release (NDC 60505-3928). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure-2 (Figure 2)
Figure-3 (Figure 3)
Figure4.jpg (Figure4)
Btl 1mg100s
This is a description of a medication called Guanfacine in extended-release tablets that contains 1mg of Guanfacine hydrochloride per tablet. The medication should be stored in a temperature-controlled environment and protected from moisture. The tablets should not be crushed or broken and it's recommended to dispense them in a tight container. The usual dosage information is available in the package insert. The medication is manufactured by Apotex Inc. in Toronto, Canada and manufactured for Apotex Corp. in Weston, Florida. *
Btl 2mg100s
This is a description for a medication containing guanfacine hydrochloride in the form of extended-release tablets. Each tablet contains 2 mg of guanfacine. The medication should be stored at a temperature between 20°C to 25°C (68°F to 77°F) and protected from moisture. The tablets should be taken without crushing or chewing. The package insert should be consulted for the usual dosage. The medication is dispensed in a tight container by Apotex Corp, which also provides Patient Information at www1.apotex.com/products/us.*
Btl 3mg100s
This is a description of a medication containing guanfacine hydrochloride in the form of an extended-release tablet. Each tablet contains 3 mg of guanfacine. The tablets should be stored at a temperature of 20°C to 25°C, with permitted excursions from 15°C to 30°C, and protected from moisture. The tablets should not be crushed, chewed, or broken before swallowing. The pharmacist should dispense the medication with patient information available at www1.apotex.com/products/us. The medication is manufactured by Apotex Inc in Toronto, Canada and is manufactured for Apotex Corp in Weston, Florida. The packaging consists of 100 tablets with NDC 60505-3929-1.*
Btl 4mg100s
This is medication information for Guanfacine Extended-Release Tablets. Each tablet contains 4mg of guanfacine as guanfacine hydrochloride, and they should not be crushed or broken before swallowing. The tablets should be stored at 20°C to 25°C, with excursions permitted from 15°C to 30°C, and protected from moisture. Dispense in a tight container. The usual dosage is available in the package insert. The medication should be dispensed with patient information. Manufactured by Apotex Inc in Toronto, Ontario, Canada, and Manufactured for Apotex Corp in Weston, Florida.*
Spd503-chemical-stucture (Spd503 Chemical Stucture)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
